Matinas Biopharma Holdings, Inc. (MTNB): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTNB Stock Price Chart Interactive Chart >
MTNB Price/Volume Stats
| Current price | $0.59 | 52-week high | $1.00 |
| Prev. close | $0.59 | 52-week low | $0.43 |
| Day low | $0.57 | Volume | 237,142 |
| Day high | $0.60 | Avg. volume | 278,728 |
| 50-day MA | $0.59 | Dividend yield | N/A |
| 200-day MA | $0.72 | Market Cap | 127.82M |
Matinas Biopharma Holdings, Inc. (MTNB) Company Bio
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections.
Latest MTNB News From Around the Web
Below are the latest news stories about MATINAS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate MTNB as an investment opportunity.
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ETBEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Monday, January 30, 2023 at 4:30 p.m. ET to provide |
12 Hot Penny Stocks On the RiseIn this article, we discuss 12 hot penny stocks on the rise. If you want to see more stocks in this selection, check out 5 Hot Penny Stocks On the Rise. Penny stocks usually trade under $5 and are favored by new investors or market participants who prefer day trading. Some key indicators that penny […] |
Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic AcidsBEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced a strategic collaboration with National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines. The parties have entered into a Material Tran |
Matinas BioPharma Holdings Inc. (AMEX: MTNB) Stock Forecast: By 2022, Bulls Expect $3.00 Per ShareIn the last trading session, 1.11 million shares of the Matinas BioPharma Holdings Inc. (AMEX:MTNB) were traded, and its beta was 1.96. Most recently the company’s share price was $0.52, and it changed around $0.02 or 3.74% from the last close, which brings the market valuation of the company to $108.50M. MTNB currently trades at … Matinas BioPharma Holdings Inc. (AMEX: MTNB) Stock Forecast: By 2022, Bulls Expect $3.00 Per Share Read More » |
How did Matinas BioPharma Holdings Inc. (MTNB) fare last session?As of Tuesday, Matinas BioPharma Holdings Inc.’s (AMEX:MTNB) stock closed at $0.57, down from $0.61 the previous day. While Matinas BioPharma Holdings Inc. has underperformed by -6.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MTNB fell by -42.82%, with highs and lows ranging from $1.16 […] |
MTNB Price Returns
| 1-mo | 26.88% |
| 3-mo | -25.32% |
| 6-mo | -32.95% |
| 1-year | -11.74% |
| 3-year | -60.40% |
| 5-year | -48.25% |
| YTD | 18.00% |
| 2022 | -50.50% |
| 2021 | -25.74% |
| 2020 | -40.09% |
| 2019 | 281.51% |
| 2018 | -48.71% |
Loading social stream, please wait...